
    
      The study included a maximum 2-week Screening Period, a maximum 4-week Titration Period for
      early-stage Parkinson's disease or maximum 7-week Titration Period for advanced-stage
      Parkinson's disease, 8-week Maintenance Period, a maximum 6-day De-escalation Period for
      early-stage Parkinson's disease or maximum 12-day De-escalation Period for advanced-stage
      Parkinson's disease and 30-day Safety Follow-Up Period.

      The maximum study durations for an individual subject with early-stage Parkinson's disease
      and with advanced-stage Parkinson's disease were 19 weeks and 23 weeks, respectively.
    
  